JHP
APYX icon

James Hambro & Partners’s Apyx Medical APYX Stock Holding History

James Hambro & Partners’s Portfolio APYX Stock Details APYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-159,542
Closed -$416K – 25
2017
Q4 		$416K Buy
+159,542
New +$498K 0.23% 22

Other funds holding APYX

ACM
Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
MAG
Millrace Asset Group Berwyn, Pennsylvania $98.4M AUM 63.71% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
HK
Horizon Kinetics New York $3.06B AUM 5.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CPA
Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return

James Hambro & Partners's APYX Position: Q1 2018 in Review

James Hambro & Partners sold out of Apyx Medical (APYX) in Q1 2018, closing a stake of 159,542 shares — an estimated $416K sold.

James Hambro & Partners first reported a position in APYX in Q4 2017 and held it in 1 quarter. The position peaked at $416K in Q4 2017. 43 funds tracked by Wall St. Rank hold APYX as of Q1 2018.

  • James Hambro & Partners reported no remaining Apyx Medical position as of Q1 2018 after selling out during the quarter.
  • James Hambro & Partners sold 159,542 Apyx Medical shares in Q1 2018, an estimated $416K.
  • James Hambro & Partners first reported a position in Apyx Medical in Q4 2017 and held it in 1 quarter.
  • James Hambro & Partners's Apyx Medical position peaked at $416K in Q4 2017.
  • 43 funds tracked by Wall St. Rank held Apyx Medical as of Q1 2018.

Based on James Hambro & Partners's 13F filing for Q1 2018, filed 30 Apr 2018.